Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.

EP: 1.Navigating mCRC: Treatment Options in the Third-Line Setting

EP: 2.Nuances With Defining “Refractory” mCRC in the Third-Line Setting

EP: 3.Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

EP: 4.Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

EP: 5.Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP: 6.Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

Now Viewing

EP: 7.Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP: 8.Unmet Needs in Third-Line mCRC: Challenges and Opportunities

1. How frequently are you observing hypertension when treating your patients with trifluridine-tipiracil plus bevacizumab? What is your monitoring and management strategy for hypertension?
2. How often do you see patients with hepatic or renal impairment in your clinical practice? What is your dosing strategy for TAS-102 plus bevacizumab for those who have hepatic or renal impairment?
3. What are some common toxicities associated with fruquintinib? How do you manage patients who may develop hypertension, hand-foot syndrome, or hepatotoxicity?
4. What are some common toxicities associated with regorafenib? How does your clinic manage potential toxicities seen with regorafenib, like hand-foot syndrome?

Related Videos